Intellectual Property
Mar. 13, 2014
Ambry Genetics beats back injunction in Myriad genetic test case
Aliso Viejo-based Ambry Genetics Corp. warded off a preliminary injunction push from Myriad Genetics Inc., causing an 8 percent drop in the Utah-based genetic test seller's shares during trading Tuesday.




By Kevin Lee
Daily Journal Staff Writer
Aliso Viejo-based Ambry Genetics Corp. warded off a preliminary injunction push from Myriad Genetics Inc., causing an 8 percent drop in the Utah-based genetic test seller's shares during trading Tuesday.
Myriad was trying to bar the sale of Ambry products that allegedly infringe its breast and ovarian cancer testing patents. The company claimed it was losing potential customers from Ambry's products, but U.S. District Judge Ro...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In